Climate Change, Floods, and Human Health | NEJM
With climate change, exposure to floods has increased and is linked to adverse health outcomes, such as injuries, diseases, and mental health harms, all of which are greater in vulnerable populations.
Related Articles
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Medical AI and Clinician Surveillance — The Risk of Becoming Quantified Workers | NEJM
Many AI innovations could benefit patients and clinicians. Yet medicine should heed lessons from industries in which AI adoption has resulted in reduced autonomy for…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy | NEJM
The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it…
Interview with I. Glenn Cohen on the professional implications of the use of artificial-intelligence–based monitoring systems in medicine. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with I. Glenn Cohen on the professional implications of the use of artificial-intelligence–based monitoring…
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…